#HVO hVIVO UK PLC – Grant of awards under Long Term Incentive Plan May 29, 2026 – Posted in: hVIVO (HVO) – Tags: awards, CEO, cfo, EBITDA, financial, LTIP, shares
London, UK – 29 May 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces that on 28 May 2026, the Company awarded 10,159,068 options under the hVIVO Long Term Incentive Plan 2024 to certain senior management, including its Chief Executive Officer and Chief Financial Officer as set out in the table below. The award is over ordinary shares of £0.001 (“Ordinary Shares”) in the form of options to acquire Ordinary Shares at nominal value (“LTIP Awards”).
|
Executive |
Role |
Number of LTIP Awards |
|
Yamin ‘Mo’ Khan |
Chief Executive Officer |
6,126,238 |
|
Stephen Pinkerton |
Chief Financial Officer |
2,289,604 |
The LTIP Awards will vest on the third anniversary of grant subject to meeting a minimum absolute total shareholder return (TSR) of 10% CAGR and mid-single digit £ million adjusted EBITDA, weighted equally, over the three-year period ending 31 December 2028.
25% of the LTIP Awards will vest on meeting the minimum threshold performance criteria outlined above, with vesting thereafter on a straight-line basis up to meeting a maximum performance target which would be achieved in the event of a 20% absolute TSR being met and a significant increase in adjusted EBITDA from the minimum threshold number.
The awards are subject to malus and clawback provisions. In making its determination in relation to the achievement of any performance target or condition under these Rules, the Remuneration Committee may, in line with the UK Corporate Governance Code, exercise its discretion to override formulaic outcomes. This includes, without limitation, to reflect overall corporate performance, the value created for shareholders, or where the business has suffered an exceptional negative event.
For further information please contact:
|
hVIVO plc |
+44 (0) 20 7756 1300 |
|||
|
Yamin ‘Mo’ Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer |
||||
|
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) |
+44 (0) 20 7220 0500 |
|||
|
Geoff Nash, Callum Davidson Trisyia Jamaludin, Harriet Ward Nigel Birks – Life Science Specialist Sales Louise Talbot – Sales |
||||
|
Peel Hunt LLP (Joint Broker) |
+44 (0)20 7418 8900 |
|||
|
James Steel, Dr Christopher Golden |
||||
|
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
|||
|
Anthony Farrell, Niall Gilchrist |
||||
|
ICR Healthcare (Financial PR & IR) Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson
|
hVIVO@icrhealthcare.com |
|||